Sanofi is ending development of tusamitamabravtansine after the antibody-drug conjugate (ADC) failed to meet the primary endpoint of a Phase III study for lung cancer. The news deals an early setback to R&D head Houman Ashrafian, who only took over the role in September, as well as the company’s ambitions in oncology.
The drugmaker added that although there was a trend for improved overall survival - the trial’s other dual primary goal - the study was terminated based on non-improvement in PFS at the final analysis. Chief medical officer Dietmar Berger remarked “although the results are not what we hoped for… We will continue to explore the potential of CEACAM5 as a biomarker in cancer types where it is highly expressed,” with the company adding that it will also continue work on antibody tusamitamab-based ADCs.
Tusamitamabravtansine, also known as SAR408701, was developed through a partnership with ImmunoGen, although Sanofi was granted an exclusive license to the ADC in 2017. According to the French company’s pipeline, tusamitamabravtansine was also being investigated in Phase II studies, both as a monotherapy and as part of combination regimens, in gastric cancer and earlier stages of lung cancer.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.